TDO2 and hepatocellular carcinoma: TDO2, for instance is expressed in diverse tumor entities including breast cancer, bladder cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, ovarian carcinoma, renal cell carcinoma, and GBM, where it promotes tumor cell motility and suppresses T cell proliferation and function (24, 47, 48).